BEAM
Price
$23.41
Change
+$0.47 (+2.05%)
Updated
Oct 4 closing price
29 days until earnings call
RXRX
Price
$6.11
Change
+$0.05 (+0.83%)
Updated
Oct 4 closing price
32 days until earnings call
Ad is loading...

BEAM vs RXRX

Header iconBEAM vs RXRX Comparison
Open Charts BEAM vs RXRXBanner chart's image
Beam Therapeutics
Price$23.41
Change+$0.47 (+2.05%)
Volume$477.4K
CapitalizationN/A
Recursion Pharmaceuticals
Price$6.11
Change+$0.05 (+0.83%)
Volume$3.85M
CapitalizationN/A
View a ticker or compare two or three
BEAM vs RXRX Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
BEAM vs. RXRX commentary
Oct 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Sell and RXRX is a Sell.

COMPARISON
Comparison
Oct 06, 2024
Stock price -- (BEAM: $23.41 vs. RXRX: $6.11)
Brand notoriety: BEAM and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 62% vs. RXRX: 73%
Market capitalization -- BEAM: $2.06B vs. RXRX: $1.97B
BEAM [@Biotechnology] is valued at $2.06B. RXRX’s [@Biotechnology] market capitalization is $1.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 5 bearish.
  • RXRX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both BEAM and RXRX are a bad buy in the short-term.

Price Growth

BEAM (@Biotechnology) experienced а -6.55% price change this week, while RXRX (@Biotechnology) price change was -12.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was -5.77%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

RXRX is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.07B) and RXRX($1.97B) have the same market capitalization . BEAM YTD gains are higher at: -13.997 vs. RXRX (-38.032). BEAM has higher annual earnings (EBITDA): -162.88M vs. RXRX (-348.35M). BEAM has more cash in the bank: 1.01B vs. RXRX (474M). RXRX has less debt than BEAM: RXRX (89.9M) vs BEAM (165M). BEAM has higher revenues than RXRX: BEAM (353M) vs RXRX (48.6M).
BEAMRXRXBEAM / RXRX
Capitalization2.07B1.97B105%
EBITDA-162.88M-348.35M47%
Gain YTD-13.997-38.03237%
P/E RatioN/AN/A-
Revenue353M48.6M726%
Total Cash1.01B474M213%
Total Debt165M89.9M184%
TECHNICAL ANALYSIS
Technical Analysis
BEAMRXRX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 23 days ago
81%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSALX22.940.28
+1.24%
Morgan Stanley Inst Intl Advtg L
VMVAX86.560.63
+0.73%
Vanguard Mid-Cap Value Index Admiral
GTTUX63.21N/A
N/A
Goldman Sachs Small Cp Val Insghts R6
MIRSX23.65N/A
N/A
Victory Integrity Small/Mid-Cap Value R6
EXEYX16.00N/A
N/A
Manning & Napier Equity Series S

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+0.83%
BEAM - RXRX
61%
Loosely correlated
+2.05%
NTLA - RXRX
59%
Loosely correlated
+1.93%
CRSP - RXRX
57%
Loosely correlated
+1.05%
PRME - RXRX
55%
Loosely correlated
+2.93%
KYMR - RXRX
51%
Loosely correlated
-0.81%
More